LYR-220, Lyra’s second product candidate, is a long-acting anti-inflammatory therapy in development for CRS patients with and without polyps who have recurrent symptoms despite prior ethmoid sinus ...
This new study, which followed patients up to 6 months after functional endoscopic sinus surgery, evaluated results using objective and subjective measures. “Nasal polyps are associated with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results